Doxorubicin and trabectedin for recurrent leiomyosarcoma – A case report
Uterine leiomyosarcoma (LMS) represents a rare yet highly aggressive tumor, comprising approximately 1% of uterine malignancies. First-line regimens involving doxorubicin or gemcitabine and docetaxel demonstrate modest response rates. Notably, the combination of doxorubicin plus trabectedin has emer...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Elsevier
2024-10-01
|
| Colección: | Gynecologic Oncology Reports |
| Materias: | |
| Acceso en línea: | http://www.sciencedirect.com/science/article/pii/S2352578924001760 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|